HSA
SPRY icon

Hussman Strategic Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Hussman Strategic Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-147,000
Closed -$1.48M – 351
2025
Q3 		$1.48M Buy
147,000
+42,000
+40% +$603K 0.32% 143
2025
Q2 		$1.83M Buy
+105,000
New +$1.52M 0.42% 96

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hussman Strategic Advisors's SPRY Position: Q4 2025 in Review

Hussman Strategic Advisors sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 147,000 shares — an estimated $1.48M sold.

Hussman Strategic Advisors first reported a position in SPRY in Q2 2025 and held it in 2 quarters. The position peaked at $1.83M in Q2 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Hussman Strategic Advisors reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Hussman Strategic Advisors sold 147,000 ARS Pharmaceuticals shares in Q4 2025, an estimated $1.48M.
  • Hussman Strategic Advisors first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Hussman Strategic Advisors's ARS Pharmaceuticals position peaked at $1.83M in Q2 2025.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Hussman Strategic Advisors's 13F filing for Q4 2025, filed 2 Feb 2026.